次增持计划不触及要约收购，不会导致公司控股股东及实际控制人发生变 化。 相关风险提示：本次增持计划实施可能存在因资本市场情况发生变化等因 素，导致增持计划延迟实施或无法完成实施的风险。如增持计划实施过程 中出现上述风险情形，公司将及时履行信息披露义务，敬请广大投资者注 意投资风险。 一、增持主体的基本情况 证券代码：688222 证券简称：成都先导 公告编号：2025-018 成都先导药物开发股份有限公司关于 宁波聚智先导生物科技合伙企业（有限合伙） 增持公司股份计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次增持主体宁波聚智先导生物科技合伙企业（有限合伙）（以下简称"聚 智先导"）为成都先导药物开发股份有限公司（以下简称"公司"或"成都先 导"）持股 5%以上股东、员工持股平台，与公司控股股东、实际控制人 JIN LI（李进）为一致行动人关系。截至本公告披露日，聚智先导持有公司 38,651,163 股股份，占总股本的比例为 9.65%，JIN LI（李进）持有公司 81,876,9 ...

成都先导公告，持股5%以上股东聚智先导计划2500万元-5000万元增持公司股份，资金来源为自有资金 及专项贷款。 ...

Group 1 - The core viewpoint of the article highlights Chengdu Xian Dao's current stock performance, with a closing price of 15.82 yuan, an increase of 1.54%, and a rolling PE ratio of 96.48, marking a new low in 20 days, with a total market value of 6.339 billion yuan [1] - Chengdu Xian Dao ranks 40th in the medical services industry based on PE ratio, which has an average of 38.66 and a median of 38.36 [1] - As of March 31, 2025, the number of shareholders for Chengdu Xian Dao has increased to 16,254, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - The main business of Chengdu Xian Dao includes drug early discovery and development services related to DEL technology, offering services such as DEL screening, DEL library customization, FBDD/SBDD, custom drug development, compound structure intellectual property transfer, and chemical synthesis [1] - In the latest quarterly report for Q1 2025, the company achieved an operating income of 107 million yuan, a year-on-year decrease of 0.60%, while net profit reached 28.2844 million yuan, a year-on-year increase of 102.90%, with a gross profit margin of 51.87% [1]

证券代码：688222 证券简称：成都先导 公告编号：2025-017 成都先导药物开发股份有限公司 关于筹划重大资产重组事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 风险提示 本次交易不构成关联交易。经初步测算，本次交易预计构成《上市公司重大 资产重组管理办法》规定的重大资产重组情形。本次交易不涉及公司发行股份， 也不会导致公司控制权的变更。 二、本次筹划重大资产重组事项的进展情况 2025 年 3 月 31 日，公司与标的公司及其控股股东、实际控制人邹巧根签署 了《股权收购意向书》，内容详见公司于 2025 年 4 月 1 日在上海证券交易所网站 （www.sse.com.cn）披露的《成都先导药物开发股份有限公司关于筹划重大资产 重组暨签署<股权收购意向书>的提示性公告》（公告编号：2025-004）。 截至本公告披露之日，公司及有关各方正在积极推进本次重组的相关工作， 具体方案仍在谨慎筹划论证中，公司将继续按照《上市公司重大资产重组管理办 法》及其他相关规定，及时履行信息披露义务。 三、风险提示 ...

证券代码：688222 证券简称：成都先导 成都先导药物开发股份有限公司 2024 年年度股东大会会议资料 2024 年年度股东大会会议资料目录 | 2024 | 年年度股东大会会议资料目录 2 | | | --- | --- | --- | | 2024 | 年年度股东大会会议须知 | 3 | | 2024 | 年年度股东大会会议议程 | 6 | | 2024 | 年年度股东大会会议议案 | 8 | | 议案一：关于审议公司 | 年年度报告及其摘要的议案 2024 | 8 | | 议案二：关于审议公司 | 2024 年度董事会工作报告的议案 | 9 | | 议案三：关于审议公司 | 2024 年度监事会工作报告的议案 | 16 | | 议案四:关于审议公司 | 年度财务决算报告的议案 2024 | 20 | | 议案五：关于审议公司 | 2024 年度利润分配预案的议案 24 | | | 议案六：关于续聘公司 | 年度财务及内部控制审计机构的议案 25 2025 | | | 议案七：关于审议公司 | 2025 年度财务预算报告的议案 26 | | | 议案八：关于审议公司 | 2025 年度董事薪酬方案的议 ...

Investment Rating - The report maintains a "Recommended" rating for Chengdu Xian Dao (688222.SH) [4][6] Core Views - Chengdu Xian Dao achieved a revenue of 427 million yuan in 2024, representing a year-on-year increase of 14.99%, and a net profit attributable to shareholders of 51 million yuan, up 26.13% year-on-year [1] - In Q1 2025, the company reported a revenue of 107 million yuan, a slight decline of 0.60% year-on-year, while the net profit attributable to shareholders surged by 102.90% to 28 million yuan [1][2] - The gross margin for Q1 2025 improved to 48.13%, an increase of 2.92 percentage points year-on-year and 5.83 percentage points quarter-on-quarter [2] - The company is focusing on enhancing its foundational capabilities through AI integration, which is expected to accelerate drug discovery processes [4] Summary by Sections Financial Performance - In 2024, the revenue breakdown by business segments shows: 1. DEL segment generated 199 million yuan, up 8.55% year-on-year 2. FBDD/SBDD segment achieved 120 million yuan, up 30.99% year-on-year 3. OBT segment reported 48 million yuan, up 39.72% year-on-year [3] - The projected revenues for 2025-2027 are 515 million, 614 million, and 722 million yuan, with growth rates of 20.6%, 19.1%, and 17.7% respectively [4][6] Profitability Metrics - The net profit attributable to shareholders is forecasted to be 65 million, 84 million, and 103 million yuan for 2025, 2026, and 2027, with growth rates of 27.3%, 28.9%, and 22.7% respectively [6][9] - The PE ratios for the same years are projected to be 91, 71, and 58 [6][9] Strategic Initiatives - The company has successfully built a DMTA molecular optimization infrastructure combining DEL and AI, which enhances the efficiency of drug development [4] - The integration of AI is expected to reduce trial and error costs while accelerating the transition from target discovery to clinical candidates [4]

成都先导 20250428 摘要 • 成都先导拥有药物发现与开发、核酸平台、蛋白降解机制及化学和生物技 术服务四大核心技术平台，其中药物发现与开发占比接近 50%，核酸平台 收入快速增长，蛋白降解机制板块在特殊配体及商业转换方面取得突破。 • 公司客户数量快速增长，从 2022 年的 200 多家增加到 2024 年的超过 500 家，潜在商业线索客户超过 2000 家，反映出商务拓展取得显著成果。 全球收入占比具有韧性，美国市场占比约 40%，欧洲增速明显达 34%左 右，国内业务占比增长到 16%左右。 • 公司 2024 年销售业务保持 75%左右的整体毛利率，FBDD 板块毛利率显 著提升，TPD 板块毛利率接近 40%。研发投入占比维持在 15%至 20%区 间，主要受集团营收体量变大及外部环境影响。 • 公司转让超过 1,100 个带有活性的化合物实体，IP 数量超过 110 个，为 客户筛选覆盖 53 类靶点，总计超过 700 个全球具有挑战性的靶点。 HG146 实体瘤项目已进入临床二期，L17 炎症项目进入第二代探索阶段。 • 公司正在建设基于 AI 加 DMTA 全自动化分子优化能力平台， ...

Group 1 - The core viewpoint of the article highlights Chengdu Xian Dao's stock performance, with a closing price of 14.88 yuan, up 5.08%, and a rolling PE ratio of 90.75, marking a new low in 17 days, with a total market value of 5.962 billion yuan [1] - Chengdu Xian Dao ranks 37th in the medical services industry, which has an average PE ratio of 40.74 and a median of 42.36 [1] - As of March 31, 2025, the number of shareholders for Chengdu Xian Dao increased to 16,254, with an average holding value of 352,800 yuan and an average holding of 27,600 shares [1] Group 2 - Chengdu Xian Dao specializes in drug discovery and development services related to DEL technology, including DEL screening services, custom DEL libraries, FBDD/SBDD, custom drug development, compound structure intellectual property transfer, and other related services [1] - In the latest quarterly report for Q1 2025, the company reported revenue of 107 million yuan, a year-on-year decrease of 0.60%, while net profit reached 28.2844 million yuan, a year-on-year increase of 102.90%, with a gross profit margin of 51.87% [1]

Core Insights - Chengdu Xian Dao's revenue for 2024 reached 427 million yuan, marking a year-on-year growth of 14.99%, achieving a historical high [1] - The company's net profit attributable to shareholders, excluding non-recurring gains and losses, surged by 1563.94% to 57.44 million yuan [1] - In Q1 2025, the company maintained a robust growth trajectory with revenue of 107 million yuan and a net profit of 17.51 million yuan, reflecting a year-on-year increase of 113.63% [1] Business Performance - The DEL (DNA-encoded library) segment, a cornerstone of the company, generated approximately 200 million yuan in revenue, up 8.55% year-on-year, solidifying its industry-leading position [1] - The drug design business, benefiting from milestone revenue recognition from the UK subsidiary Vernalis, reported revenue of about 120 million yuan, a 30.99% increase [1][2] - The delivery molecule commercialization project achieved a breakthrough in revenue conversion, generating 48.03 million yuan, a 39.72% increase [2] - Chemical services and biological services segments reported revenues of 17.07 million yuan and 18.37 million yuan, reflecting year-on-year growth of 8.09% and 15.71% respectively [2] R&D Investment - In 2024, the company invested 67.33 million yuan in R&D, accounting for 15.77% of its revenue, and secured 32 authorized invention patents while submitting 27 new patent applications [3] - The company published 8 scientific papers in core industry journals and 5 peer-reviewed papers, indicating a continuous enhancement of its technological innovation and academic contributions [3] - The self-developed drug pipeline, HG146, officially entered clinical phase II by the end of 2024, showcasing the company's commitment to advancing its proprietary research [3] Strategic Positioning - The establishment of the first global DEL alliance with major international pharmaceutical companies aims to share resources and accelerate drug discovery [2] - The company has built a "technology moat + financial stability + strategic foresight" framework, demonstrating resilience and growth potential in the biopharmaceutical sector [4] - The explosive growth in 2024 and Q1 2025 is attributed to the commercialization breakthroughs of core technology platforms and strategic ecological layout [4]

成都先导药物开发股份有限公司 （一）出席董事会及股东大会情况 2024 年度独立董事述职报告 本人郭云沛作为成都先导药物开发股份有限公司（以下简称"成都先导"或 "公司"）独立董事，在 2024 年度严格按照《中华人民共和国公司法》、《中 华人民共和国证券法》《上市公司独立董事管理办法》《上市公司治理准则》等 法律法规、规范性文件以及《公司章程》《公司独立董事工作制度》的规定和要 求，本着客观、公正、独立的原则，勤勉尽责、独立履职，及时了解公司的生产 经营及发展情况，促进公司规范运作、健康发展，维护公司、全体股东特别是中 小股东的利益。现将 2024 年度工作情况报告如下： 一、基本情况 （一）个人工作履历、专业背景等基本情况 郭云沛，1947 年 7 月出生，中共党员，中国国籍，无境外永久居留权。于 1988 年毕业于四川广播电视大学新闻传播专业，大学专科学历，具有高级编辑 职称。1969 年 2 月至 1973 年 6 月，本人应征入伍任宣传干事；1973 年 6 月至 1983 年 10 月，任职于重庆桐君阁制药厂中层员工；1983 年 10 月至 2007 年 10 月，任国家药品监督管理局(注：原为 ...